IDEAS home Printed from https://ideas.repec.org/a/eur/ejisjr/97.html
   My bibliography  Save this article

Utilization Trends of Endocrine Therapies for Breast Cancer in Albania During 2004-2014

Author

Listed:
  • Laerta Kakariqi

    (MD, PhD, Department of Biomedical and Experimental Subjects, Pharmacology Section, Faculty of Medicine, University of Medicine, Albania)

Abstract

Aim: To evaluate the patterns of use of the out-of-hospital endocrine therapies for breast cancer in Albania during the period 2004-2014. Methods: The study was retrospective and we analyzed the prescription and consumption of these drug classes in the primary health care in Albania during 2004-2014. All data were collected from Health Insurance Institute (HII)(1) and analysed reflecting the ambulatory and outpatient use for the period 2004-2014. The data about the consumption of drugs were expressed as a number of Defined Daily Dose (DDDs) /1000 inhabitants/day. Utilization was measured in DDD/1000 inhabitants/day and was also compared with breast cancer morbidity/1000 inhabitants, to understand the covering of the population from the reimbursement scheme. For all the period under study 2004-2014, there were collected and analysed the data of import and domestic production of drugs, which altogether represent the real consumption of drugs in the country. These data were subsequently included in a comparative analysis with the utilization data according to the HII. Results: The drug with the highest values of consumption is Letrozole 0.05-0.37 DDD/1000 inhabitants/day2004-2014). Anastrazole was introduced to the scheme in 2008. Its consumption in2014 was 0.26 DDD/1000 inhabitants/day. The consumtion of Tamoxifen is reduced through these years with values 0.32-0.17 DDD/1000 inhabitants/day respectively 2004-2014. Breast cancer morbidity data indicate that there does exist a correlation statistically significant between this disease and the trend of consumption of endocrine therapies drugs (p = 0,0009) Conclusions: It is evident that a non-small part of the patients remain untreated under the scheme. There is noted a shift in use of endocrine therapy from tamoxifen to aromatase inhibitors. This trend is consistent with major international clinical guidelines that recomend preferential use of aromatase inhibitors in post-menopausal women.

Suggested Citation

  • Laerta Kakariqi, 2021. "Utilization Trends of Endocrine Therapies for Breast Cancer in Albania During 2004-2014," European Journal of Interdisciplinary Studies Articles, Revistia Research and Publishing, vol. 2, May - Aug.
    • Handle: RePEc:eur:ejisjr:97
    DOI: 10.26417/ejis.v2i3.51-56
    as

    Download full text from publisher

    File URL: https://revistia.com/index.php/ejis/article/view/1531
    Download Restriction: no
    File URL: https://revistia.com/files/articles/ejis_v2_i3s_16/Laerta.pdf
    Download Restriction: no
    File URL: https://libkey.io/10.26417/ejis.v2i3.51-56?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eur:ejisjr:97. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Revistia Research and Publishing (email available below). General contact details of provider: https://revistia.com/index.php/ejis .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.